Business context and reporting period
Filing identity: The supplied filing is Sigma Labs, Inc.’s Form 10-K, not a Nexttrip, Inc. filing. It reports the fiscal year ended December 31, 2017, with 2016 comparatives; it is not a quarterly report for 2017 Q4.
Sigma Labs develops PrintRite3D in-process quality-assurance technology for metal additive manufacturing, and also earns revenue from engineering services and contract manufacturing. Its strategy shifted in 2017 from research-focused customers toward manufacturers already producing metal parts and seeking to improve production yields.
Financial performance and position
| Metric | 2017 | 2016 |
|---|---|---|
| Revenue | $641,049 | $966,422 |
| Gross profit | $368,677 | $737,520 |
| Gross margin | 57.5% | 76.4% |
| Operating expenses | $4,420,667 | $3,211,258 |
| Net loss | $4,577,516 | $2,196,834 |
| Net loss per share | $1.04 | $0.70 |
| Cash used in operations | $2,791,406 | $1,962,314 |
- Revenue fell about 34%; net loss more than doubled. Operating costs rose about 38%, while gross profit declined about 50%.
- Cash at year-end was $1,515,674, compared with $398,391 a year earlier. Working capital was a surplus of $2,273,801, versus $110,799.
- Total assets were $3,394,810 and total liabilities were $382,894 at December 31, 2017. Stockholders’ equity was $3,011,916.
- Cash provided by financing was $4,837,649, principally reflecting the February 2017 equity-and-warrant offering. Investing cash use was $928,960, including $788,500 in notes receivable.
- Year-end notes payable were $100,000, net of discounts; the remaining convertible note was due by May 18, 2018 or upon a qualifying offering. No credit line was available.
Material changes and unusual items
- Management attributed lower revenue to the mid-year strategic reorganization and the decision to focus sales on customers with active metal-part production.
- Payroll and benefits increased to $1,509,672 from $1,230,267; stock-based compensation rose to $719,796 from $341,558. Research and development costs increased to $302,043 from $120,638.
- Other expense was $525,526, compared with other income of $276,904 in 2016. This included $545,188 of derivative revaluation and debt-discount amortization charges, partly offset by state incentives and interest income.
- In 2017, the company raised approximately $5.23 million net in a public offering, repaid $500,000 of note principal, and converted $400,000 of principal plus accrued interest into shares. Year-end outstanding warrants totaled 1,434,000.
Outlook, risks and contingencies
Management expected higher commercialization, sales and marketing activity in 2018, while also anticipating increased operating costs. It stated that cash, anticipated revenue, the March 2018 collection of the Morf3D note, and the April 2018 financing were expected to fund operations through 2018. Management also anticipated potentially significant sales contracts in 2018, but provided no quantified revenue or earnings guidance and gave no assurance those contracts would close.
- The company has a history of losses and negative operating cash flow, and stated that revenue was insufficient to fund operations. Future financing may be needed and could dilute shareholders or impose onerous terms.
- Revenue is concentrated: four customers each represented more than 10% of 2017 revenue; the largest represented 28.75%. Three customers accounted for more than 10% each of year-end receivables.
- Key risks include successful commercialization and customer adoption, competition from larger companies, dependence on key personnel, intellectual-property protection, government-contract compliance, customer termination, and the possibility of additional dilution. The company reported no current legal proceedings.
- Subsequent events: Morf3D repaid the note and accrued interest in March 2018 (reported as approximately $535,000); an April 2018 private placement produced approximately $840,000 net. That placement included Series B preferred stock initially convertible into 1,000,000 common shares and warrants for 750,000 shares, plus placement-agent warrants for 140,000 shares.
- Management reported effective disclosure controls and internal control over financial reporting at year-end; the auditor did not attest to internal-control effectiveness. The financial-statement audit opinion was unqualified.
- The filing contains an inconsistency in accumulated deficit: the risk-factor discussion states $14,411,470, while the balance sheet reports $14,338,470.
Investor verification priorities
- Confirm the issuer and reporting period: this filing is Sigma Labs’ 2017 annual report, not Nexttrip’s filing or a quarterly report.
- Review audited statements and notes for the loss, cash burn, revenue decline, customer concentration and the accumulated-deficit discrepancy.
- Verify the 2018 financing terms, conversion and warrant dilution, and the status of any remaining debt and note receivables.
- Assess whether the anticipated production-focused contracts and commercialization progress translated into recurring revenue and improved cash generation.
- Check subsequent filings for liquidity updates, actual contract wins, share-count changes and Nasdaq listing compliance.